Bp Plc trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,000 shares of the pharmaceutical company’s stock after selling 5,000 shares during the period. Bp Plc’s holdings in Vertex Pharmaceuticals were worth $4,474,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of VRTX. Oregon Public Employees Retirement Fund grew its stake in Vertex Pharmaceuticals by 16,530.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock worth $28,000 after purchasing an additional 4,583,156 shares during the period. We Are One Seven LLC purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth $32,000. Quantamental Technologies LLC purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth $41,000. Hanseatic Management Services Inc. grew its stake in shares of Vertex Pharmaceuticals by 52.0% in the fourth quarter. Hanseatic Management Services Inc. now owns 298 shares of the pharmaceutical company’s stock worth $49,000 after acquiring an additional 102 shares during the last quarter. Finally, Essex Savings Bank purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth $51,000. 95.40% of the stock is currently owned by institutional investors.
Vertex Pharmaceuticals stock opened at $185.25 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 2.98. Vertex Pharmaceuticals Incorporated has a one year low of $144.07 and a one year high of $195.81. The firm has a market cap of $46.34 billion, a P/E ratio of 65.46, a price-to-earnings-growth ratio of 2.16 and a beta of 1.65.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Tuesday, February 5th. The pharmaceutical company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.06 by $0.24. Vertex Pharmaceuticals had a return on equity of 24.15% and a net margin of 68.81%. The company had revenue of $870.11 million for the quarter, compared to analysts’ expectations of $818.29 million. During the same period last year, the firm posted $0.61 earnings per share. Vertex Pharmaceuticals’s revenue was up 33.5% compared to the same quarter last year. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 3.22 EPS for the current fiscal year.
In related news, CEO Jeffrey M. Leiden sold 111,431 shares of the stock in a transaction on Monday, February 11th. The stock was sold at an average price of $180.24, for a total transaction of $20,084,323.44. Following the sale, the chief executive officer now directly owns 223,916 shares of the company’s stock, valued at $40,358,619.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Paul M. Silva sold 809 shares of the stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $186.52, for a total value of $150,894.68. Following the sale, the senior vice president now directly owns 16,896 shares in the company, valued at $3,151,441.92. The disclosure for this sale can be found here. Insiders have sold 184,887 shares of company stock worth $33,658,261 over the last ninety days. 0.75% of the stock is currently owned by insiders.
A number of research firms have recently commented on VRTX. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 7th. BMO Capital Markets increased their target price on Vertex Pharmaceuticals to $234.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 6th. Zacks Investment Research raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 26th. Maxim Group cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 6th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $217.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 27th. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $203.79.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for treating cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for treating patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.
Featured Article: Analyst Ratings Trading
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.